Methods of making a spheroid are provided whereby a suspension is first produced including one or more biologically-relevant materials dispersed within a biocompatible medium. A droplet of the suspension is then bioprinted into a salt solution by bringing the droplet into contact with a surface of the salt solution in a controlled manner to reproducibly yield a spheroid containing a desired size and a desired amount of biologically-relevant materials.

The technology relates in part to epithelial cell spheroids and methods of producing epithelial cell spheroids.

The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel.

Among the various aspects of the present disclosure is the provision of methods, synthetic DC, and compositions for T cell activation. The present disclosure provides for synthetic dendritic cells (DCs), methods of generating synthetic dendritic cells (DCs), methods of generating T cell-encapsulated gelatin microspheres and microcapsules, methods of activating T cells using synthetic DCs, methods for expanding T cells against individualized antigen-specific mutational antigens using synthetic DCs, and methods of treating a chronic disease (e.g., HIV, HPV) or cancer using the synthetic DCs.

Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

A method of preparing and obtaining cell aggregates having increased oxygenation abilities. The method includes the preparation of fluorinated polymeric microparticles. Once the fluorinated polymeric microparticles are prepared, they are combined with mammalian cells to create the cell aggregates having increased oxygenation.

Provided are a cell-containing hydrogel body and a method of producing the same, which enable simple and effective control of the size of a boundary surface for an interaction between cells. The method of producing a cell-containing hydrogel body includes: forming, under a gas phase, a first hydrogel droplet on a surface of a substrate, the first hydrogel droplet containing first cells being dispersed therein and a first hydrogel polymer; forming, under a gas phase, a second hydrogel droplet on the surface, the second hydrogel droplet containing second cells being dispersed therein and a second hydrogel polymer, the second hydrogel droplet being combined with the first hydrogel droplet; and forming, under a gas phase, a cell-containing hydrogel body on the surface by gelling a hydrogel droplet-combined body including a first droplet portion derived from the first hydrogel droplet and a second droplet portion derived from the second hydrogel droplet.

Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.

The present invention provides a novel means for storing and/or transporting multicellular aggregates. The multicellular aggregates comprise a plurality of adjoining cells, wherein the aggregate is entrapped or encapsulated in a reversibly cross-linked hydrogel and the entrapped or encapsulated aggregate is packaged in a sealed receptacle. Methods for preparing such aggregates for storage and/or transportation from a first location to a second location are also provided, together with related methods for transporting or storing said aggregates and methods for fulfilling an order or request for said aggregates.

A mitochondrion-targeting protein nanoparticle, containing related information such as an amino acid sequence thereof, a coding nucleic acid sequence, and a vector and a host expression bacterium for the coding nucleic acid. Under the induction of metal ions, the self-assembled protein nanoparticle mentioned above can be obtained by an Escherichia coli expression system. The protein nanoparticle can be applied in cancer diagnosis and treatment. Compared with existing mitochondrion-targeting small molecules (such as TPP and MPP), the protein nanoparticle can achieve properties of tumor enrichment, mitochondrion targeting, increasing of ROS content in cells, induction of cell apoptosis, inhibiting tumor growth, etc.